Cashu
Viking Therapeutics to Showcase Innovations and Pipeline at Upcoming Healthcare Conferences
4 days ago
Stocks
Health Care
vktx
Viking Therapeutics
NASDAQ: VKTX
+1.26 (+3.64%)
35.92
USD
At close at Mar 11, 20:39 UTC
Overview
Loading chart...
Key Stats
Market Cap
4.04B
Dividend Yield
0.00%
P/E Ratio
-11.24
EPS
-1.00
Revenue
-
Avg. Volume
2.87M
About
What does VKTX do?
Viking Therapeutics, based in San Diego, develops therapies for metabolic and endocrine disorders, including VK2809 for NASH, VK0214 for X-ALD, and VK2735 for metabolic issues. The company went public on April 29, 2015, and has 28 employees.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.